Company Filing History:
Years Active: 1998-2003
Title: The Innovations of Michael B. Widmer
Introduction
Michael B. Widmer is a notable inventor based in Seattle, WA. He has made significant contributions to the field of immunology, particularly in relation to CD40 ligand gene mutations. With a total of 3 patents, his work has advanced the understanding and treatment of various immunodeficiencies.
Latest Patents
Widmer's latest patents focus on defective CD4+ T-cells that express active CD40-L. These CD4 cells are obtained from individuals with a defective CD40L gene and are transfected with a vector containing CD40-L. His patents also disclose methods for detecting mutations in the CD40 ligand gene. This involves isolating nucleic acid from an individual, selectively amplifying it, and analyzing the amplified nucleic acid for mutations. Furthermore, he has developed methods for treating individuals with a defective CD40 ligand gene, including those with X-linked hyper IgM and combined variable immunodeficiency. Additionally, his work includes the creation of non-human animals that lack functional CD40 ligand due to gene targeting technology.
Career Highlights
Michael B. Widmer has been associated with Immunex Corporation, where he has contributed to groundbreaking research in immunology. His work has not only advanced scientific knowledge but has also paved the way for potential therapeutic applications.
Collaborations
Widmer has collaborated with esteemed colleagues such as Melanie K. Spriggs and Richard Jeffrey Armitage. These collaborations have further enriched his research and innovation in the field.
Conclusion
Michael B. Widmer's contributions to immunology through his patents and research have had a profound impact on the understanding and treatment of immunodeficiencies. His work continues to inspire advancements in medical science.